REGULATORY
MHLW Study Group Postpones Decision on Relief System for Victims of Health Damages Due to Anticancer Drugs
At a meeting on November 18, the Ministry of Health, Labor and Welfare’s (MHLW; Korosho) Study Group on the Relief of Health Damage Caused by Anticancer Drugs (chairman: Professor Emeritus Akio Morishima, Nagoya University) decided to postpone its results for…
To read the full story
REGULATORY
- MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026
- Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
- Japan Allows Flexibility on Pharmacopoeia Test Differences in Supply Crunch
April 28, 2026
- Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
- LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





